Anlon Healthcare Ltd , fresh from its September 2025 IPO listing, has signed a Share Purchase Agreement (SPA) to acquire a stake in Bizotic Lifescience valued at ₹38 million. The move expands its pharmaceutical intermediates and API portfolio through strategic consolidation in the high-growth healthcare sector.
Anlon Healthcare Ltd, the Rajkot-based manufacturer of pharmaceutical intermediates, APIs, nutraceuticals, and veterinary products, announced execution of a Share Purchase Agreement for acquiring equity stake in Bizotic Lifescience Private Limited worth approximately ₹38 million. The transaction follows Anlon's successful ₹121 crore IPO in August-September 2025, which listed strongly on BSE and NSE.
The acquisition aligns with Anlon's growth strategy post-IPO, leveraging FY25's robust 81% revenue surge to ₹120 crore and 112% PAT growth to ₹20.5 crore. Bizotic Lifescience complements Anlon's 65+ commercial products exported to 15+ countries, enhancing manufacturing capacity and product pipeline amid rising global demand for high-purity APIs.
Deal completion is subject to customary approvals and conditions precedent. This inorganic expansion supports Anlon's capex plans funded by IPO proceeds, positioning it competitively in regulated markets with WHO-GMP and ISO certifications.
Key highlights
-
Deal value: ₹38 million stake acquisition in Bizotic Lifescience via SPA.
-
Strategic fit: Bolsters API/nutraceutical portfolio post-IPO growth.
-
Anlon FY25: Revenue +81% to ₹120 Cr; PAT +112% to ₹20.5 Cr.
-
IPO context: Listed Sep 2025 after ₹121 Cr fresh issue raise.
Sources: Chittorgarh IPO tracker; JM Financial; Groww; Paytm Money; Business Standard.